hemming& Wealth Management Inc. Invests $777,000 in Stryker Corporation $SYK

hemming& Wealth Management Inc. acquired a new stake in Stryker Corporation (NYSE:SYK) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 2,206 shares of the medical technology company’s stock, valued at approximately $777,000. Stryker accounts for about 0.5% of hemming& Wealth Management Inc.’s holdings, making the stock its 11th biggest position.

Several other institutional investors and hedge funds have also recently bought and sold shares of SYK. Vanguard Group Inc. raised its holdings in shares of Stryker by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after buying an additional 133,892 shares during the last quarter. State Street Corp boosted its position in shares of Stryker by 2.1% during the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after buying an additional 311,507 shares during the period. Geode Capital Management LLC grew its holdings in Stryker by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock worth $2,636,238,000 after buying an additional 69,851 shares in the last quarter. Wellington Management Group LLP grew its holdings in Stryker by 22.6% in the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after buying an additional 1,198,665 shares in the last quarter. Finally, Alliancebernstein L.P. increased its position in Stryker by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after acquiring an additional 741,542 shares during the period. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

SYK opened at $308.62 on Friday. The business has a 50 day moving average price of $313.81 and a two-hundred day moving average price of $341.71. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The company has a market capitalization of $118.31 billion, a price-to-earnings ratio of 35.72, a price-to-earnings-growth ratio of 1.97 and a beta of 0.78. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same quarter last year, the business posted $2.84 earnings per share. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts predict that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is 40.74%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. JPMorgan Chase & Co. lowered their price target on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Evercore set a $355.00 price objective on shares of Stryker in a research note on Friday, May 1st. UBS Group reduced their price objective on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a report on Tuesday, March 17th. Finally, Truist Financial reiterated a “hold” rating and issued a $330.00 target price (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $395.33.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the transaction, the vice president owned 177 shares of the company’s stock, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is owned by corporate insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.